Delving into the Latest Updates on Addrenex Pharmaceuticals, Inc. with Synapse

概览

关联

1

项与 Addrenex Pharmaceuticals, Inc. 相关的药物

ADX-415

靶点

ADRA2

作用机制

ADRA2激动剂

在研机构-

原研机构

Procter & Gamble Co.

在研适应症-

非在研适应症

原发性高血压 [+2]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

3

项与 Addrenex Pharmaceuticals, Inc. 相关的临床试验

NCT00779181 / Completed临床2期

A Phase 2, Dose-Ranging Study of the Safety and Efficacy of ADX415 Immediate-Release in the Treatment of Essential Hypertension

The purpose of this study is to determine a safe and effective dose of ADX415 for the treatment of hypertension.

开始日期2008-10-01

申办/合作机构

Addrenex Pharmaceuticals, Inc.

NCT00641329 / Completed临床3期

Phase III Evaluation of the Safety and Efficacy of CLONICEL (Clonidine HCl Sustained Release) as Add-on to Psychostimulant Medication vs. Psychostimulant Medication Alone in Children and Adolescents With ADHD

The purpose of this study is to determine if CLONICEL (clonidine HCl sustained release) is a safe and effective add-on to psychostimulant therapy in children and adolescents with attention deficit hyperactivity disorder (ADHD).

开始日期2008-02-01

申办/合作机构

Addrenex Pharmaceuticals, Inc.

NCT00556959 / Completed临床3期

A Phase III, Dose-Response Evaluation of the Efficacy and Safety of CLONICEL® (Clonidine HCl Sustained Release) vs. Placebo in the Treatment of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

The purpose of this study is to determine whether CLONICEL® (clonidine HCl sustained release) is a safe and effective treatment for children and adolescents with attention deficit hyperactivity disorder (ADHD).

开始日期2007-10-01

申办/合作机构

Addrenex Pharmaceuticals, Inc.

100 项与 Addrenex Pharmaceuticals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Addrenex Pharmaceuticals, Inc. 相关的专利（医药）

登录后查看更多信息

1

项与 Addrenex Pharmaceuticals, Inc. 相关的文献（医药）

2011-06-01·Pediatrics2区 · 医学

Clonidine Extended-Release Tablets as Add-on Therapy to Psychostimulants in Children and Adolescents With ADHD

2区 · 医学

Article

作者: Kollins, Scott H. ; Wigal, Sharon B. ; Jain, Rakesh ; Segal, Scott ; Khayrallah, Moise ; Findling, Robert L. ; Brams, Matthew

OBJECTIVE:To assess the efficacy and safety of clonidine hydrochloride extended-release tablets (CLON-XR) combined with stimulants (ie, methylphenidate or amphetamine) for attention-deficit/hyperactivity disorder (ADHD).PATIENTS AND METHODS:In this phase 3, double-blind, placebo-controlled trial, children and adolescents with hyperactive- or combined-subtype ADHD who had an inadequate response to their stable stimulant regimen were randomized to receive CLON-XR or placebo in combination with their baseline stimulant medication. Predefined efficacy measures evaluated change from baseline to week 5. Safety was assessed by spontaneously reported adverse events, vital signs, electrocardiogram recordings, and clinical laboratory values. Improvement from baseline for all efficacy measures was evaluated using analysis of covariance.RESULTS:Of 198 patients randomized, 102 received CLON-XR plus stimulant and 96 received placebo plus stimulant. At week 5, greater improvement from baseline in ADHD Rating Scale IV (ADHD-RS-IV) total score (95% confidence interval: −7.83 to −1.13; P = .009), ADHD-RS-IV hyperactivity and inattention subscale scores (P = .014 and P = .017, respectively), Conners' Parent Rating Scale scores (P < .062), Clinical Global Impression of Severity (P = .021), Clinical Global Impression of Improvement (P = .006), and Parent Global Assessment (P = .001) was observed in the CLON-XR plus stimulant group versus the placebo plus stimulant group. Adverse events and changes in vital signs in the CLON-XR group were generally mild.CONCLUSIONS:The results of this study suggest that CLON-XR in combination with stimulants is useful in reducing ADHD in children and adolescents with partial response to stimulants.

100 项与 Addrenex Pharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Addrenex Pharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息